Angiotensin i to angiotensin ii
Searched over 200M research papers
Summary
5 papers analyzed
These studies suggest that angiotensin I is primarily converted to angiotensin II by the angiotensin-converting enzyme (ACE), which plays a crucial role in blood pressure regulation and cardiovascular health.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Conversion of Angiotensin I to Angiotensin II: Mechanisms and Implications
Angiotensin-Converting Enzyme (ACE) and Its Role
The conversion of angiotensin I to angiotensin II is primarily facilitated by the angiotensin-converting enzyme (ACE). This enzyme not only converts angiotensin I to the potent vasoconstrictor angiotensin II but also inactivates bradykinin, a peptide that promotes vasodilation. ACE is found in various tissues, including the vascular endothelial cells of the lungs and peripheral blood vessels, as well as the epithelial cells of the kidney tubules. The inhibition of ACE can block the renin-angiotensin system (RAS), leading to decreased systemic blood pressure, especially in conditions where blood pressure is maintained or increased by renin.
Angiotensin II and Cardiovascular Diseases
Angiotensin II (Ang II) is a critical bioactive peptide within the RAS, playing a significant role in the development of cardiovascular diseases (CVD). Ang II exerts its effects primarily through the angiotensin type 1 receptor (AT1R), leading to vasoconstriction, increased blood pressure, and other deleterious cardiovascular effects. Pharmacological inhibition of ACE or blockade of Ang II binding to AT1R has been shown to provide protection against the progression of CVD.
Noncanonical Pathways and Intracrine Functions
Recent research has highlighted the existence of noncanonical pathways for Ang II formation, particularly within the human heart. One such pathway involves the dodecapeptide angiotensin-(1-12) [Ang-(1-12)], which can generate Ang II directly via chymase, bypassing the traditional ACE pathway. This alternative pathway may be crucial in understanding the mechanisms by which Ang II contributes to adverse cardiac and vascular remodeling.
Predominance of ACE Pathway in the Human Heart
Despite the presence of non-ACE pathways, studies have shown that the ACE pathway remains the predominant route for Ang II formation in the human heart. In vivo experiments involving intracoronary administration of labeled angiotensin I and the ACE inhibitor enalaprilat demonstrated that ACE is responsible for the majority of Ang II production in myocardial tissue. This finding underscores the importance of ACE in the regulation of Ang II levels within the heart.
Protective Role of ACE2 and Angiotensin (1-7)
The ACE homologue, ACE2, plays a counter-regulatory role by converting Ang II to angiotensin (1-7) [Ang (1-7)], a peptide with vasodilatory and cardioprotective effects. The ACE2-Ang (1-7) axis has been shown to counterbalance the harmful effects of the ACE-Ang II-AT1R axis. Elevated expression of ACE2 and Ang (1-7) in failing heart tissue suggests a protective role, potentially offering therapeutic benefits in cardiovascular conditions.
Conclusion
The conversion of angiotensin I to angiotensin II is a critical process mediated predominantly by ACE, with significant implications for cardiovascular health. While noncanonical pathways and intracrine functions of Ang II add complexity to this system, the ACE pathway remains the primary route for Ang II formation in the heart. Understanding these mechanisms provides valuable insights into potential therapeutic strategies for managing cardiovascular diseases.
Sources and full results
Most relevant research papers on this topic
